AG2304 vs Atozet (ezetimibe/atorvastatin)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline

AG2304

Developed by Ahn-Gook Pharmaceutical

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule (combination)
Partial signal

NCT06717360 · Phase 3 · completed

The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.

No aligned efficacy figure on record for this race.

Atozet (ezetimibe/atorvastatin)

Rights held by Organon and partners; US product discontinued

small molecule combination
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAG2304Atozet (ezetimibe/​atorvastatin)
LDL-C, % change—Not posted · NCT06717360-49.0% vs -27.8%vs Atorvastatinwk 6 · n 65NCT05761444
1 other result
  • -50.4% vs -34.4% wk 12 · n 60 · Phase 4 · secondary NCT05761444
Non-HDL-C, % change—Not posted · NCT06717360—Not reported
ApoB, % change—Not posted · NCT06717360—Not reported
Lp(a), % change—Not posted · NCT06717360—Not reported
3-point MACE (% with event)—Not posted · NCT06717360—Not reported

LDL-C, % change

AG2304
—Not posted · NCT06717360
Atozet (ezetimibe/​atorvastatin)
-49.0% vs -27.8%vs Atorvastatinwk 6 · n 65NCT05761444
1 other result
  • -50.4% vs -34.4% wk 12 · n 60 · Phase 4 · secondary NCT05761444

Non-HDL-C, % change

AG2304
—Not posted · NCT06717360
Atozet (ezetimibe/​atorvastatin)
—Not reported

ApoB, % change

AG2304
—Not posted · NCT06717360
Atozet (ezetimibe/​atorvastatin)
—Not reported

Lp(a), % change

AG2304
—Not posted · NCT06717360
Atozet (ezetimibe/​atorvastatin)
—Not reported

3-point MACE (% with event)

AG2304
—Not posted · NCT06717360
Atozet (ezetimibe/​atorvastatin)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AG2304: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AG2304: 0 of 4 rows · Atozet (ezetimibe/atorvastatin): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAtozet (ezetimibe/​atorvastatin)
Dropout rate
11.9%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
Discontinued due to AEs
3%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
Serious AEs
6%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
Most frequent reported AEs
alanine aminotransferase increased 1.5%
alopecia 1.5%
anaemia 1.5%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Atozet (ezetimibe/atorvastatin)

LDL-C -48.97% (n=65) vs -27.75% (n=67) Atorvastatin @ 6wk
percent change · % of baseline
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
show 1 more result
-50.37% (n=60) vs -34.41% (n=65) Atorvastatin @ 12wk
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
LDL-C Less Than 55 46.2% (n=65) vs 9% (n=67) Atorvastatin @ 6wk
responder rate · % of participants
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
show 1 more result
55% (n=65) vs 15.4% (n=67) Atorvastatin @ 12wk
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
LDL-C Less Than 70 78.5% (n=65) vs 38.8% (n=67) Atorvastatin @ 6wk
responder rate · % of participants
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
show 1 more result
85% (n=65) vs 58.5% (n=67) Atorvastatin @ 12wk
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304's landscape · Atozet (ezetimibe/atorvastatin)'s landscape